Lindis Biotech selects Celonic Group for commercial manufacturing of catumaxomab
LINDIS Biotech GmbH has selected Swiss Celonic Group to manufacture its recently EU-approved malignant ascites treatment catumaxomab for commercial supply.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1185 entries already.
Entries by Thomas Gabrielczyk
Cultivated B solves fetal bovine serum problem
/in News/by Thomas GabrielczykGerman-Canadian food tech specialist The Cultivated B reports that it has identified a small molecule that can replace bovine fibroblast growth factor (bFGF) in the production of cell-based meat with a stable, scalable small molecule that results in reproducible quality of sustainably cultured meat.
naturalX secures €100m to fuel the future of consumer health in Europe
/in News/by Thomas GabrielczykThe new fund supports of NaturalX, which has its first closing at €100m, supports proactive healthcare, filling a market gap as consumers take control of their own health journey.
BRAIN Biotech partners with PX Group in microbial gold recycling
/in News/by Thomas GabrielczykGerman BRAIN Biotech AG and the Switzerland’s PX Group will extend its partnership within the framework of the PX Urban Mining Initiative. The extension builds on previous work, which focused on providing a proof of concept for the biological recovery of gold from e-waste and other gold-containing side streams.
Axplora Group announces €50m expansion of GLP-1 manufacturing site
/in News/by Thomas GabrielczykGerman API and antibody drug conjugate (ADC) CDMO Axplora Group GmbH has announced an investment of €50m in its Mourenx site in Southwest France, securing its position as a key player in the fight against cardiovascular and metabolic diseases.
Ethris GmbH bags US$5m from CEPI
/in News/by Thomas GabrielczykOslo-based Coalition for Epidemic Preparedness Innovations (CEPI) has granted US$5m to RNA formulation specialis Ethris to support studies that demonstrate spray-dried RNA vaccines remain stable at room temperature and are suitable for mucosal delivery.
The European Alliance for the Bioeconomy wants to bring back economic growth
/in News/by Thomas GabrielczykNow that US President Donald Trump has loudly announced his intention to withdraw from the Paris climate targets and refocus the US economy on fossil fuel production, Europe, which is still a leader in the bioeconomy, is sensing an opportunity. A new cluster alliance of 14 production sites wants to advance the high-tech bioeconomy.
Mallia selects Northway to produce alopecia therapy
/in News/by Thomas GabrielczykHair loss therapeutics developer Mallia Therapeutics and Northway Biotech have partners to set up a manufacturing process of soluble CD83 protein to prevent and cure hair loss.
Aplagon secures €7m for APAC development
/in News/by Thomas GabrielczykHelsinki-based Aplagon has secured €7m in financing to advance its therapeutic APAC into Phase 2a clinical trials.
EC launches EU Biotech and Biomanufacturing Hub
/in News/by Thomas GabrielczykOne day after presenting its competition strategy, the EU Commission has launched an EU Biotech and Biomanufacturing Hub. The collection of information is intended to help biotech start-ups navigate through the jungle of EU funding measures and provide access to networks that help with patenting, product authorisation and compliance with EU regulations.